TOKYO - Fujifilm Holdings Corp. will continue clinical tests of its anti-flu drug Avigan, a candidate treatment for the novel coronavirus, beyond the initially scheduled end in June due to a lack of sufficient data, a company source said Monday.
Sorry. This article is no longer available.
Sorry, this article was first published more than three months ago and is temporarily unavailable.
Once the upcoming introduction of a paid membership system is fully operational, paid members will have access to all our stories.
Free Membership Provides
Newsletter from Editorial Team and access to archive articles from past three months.
By continuing, you agree to the Terms of Use,
and Privacy Policy.
